Ipsen SA IPN-FR:Euronext Paris

*Data is delayed | EUR
Last | 5:35 PM CEST
79.28quote price arrow up+1.12 (+1.43%)
Volume
105,977
52 week range
63.90 - 95.90

...

Loading . . .
  • Open78.48
  • Day High79.40
  • Day Low78.14
  • Prev Close78.16
  • 52 Week High95.90
  • 52 Week High Date09/17/20
  • 52 Week Low63.90
  • 52 Week Low Date05/14/20

Key Stats

  • Market Cap8,060.02M
  • Shares Out82.96M
  • 10 Day Average Volume119,529.27
  • Dividend1.00
  • Dividend Yield1.26%
  • Beta0.82
  • YTD % Change16.76

KEY STATS

  • Open78.48
  • Day High79.40
  • Day Low78.14
  • Prev Close78.16
  • 52 Week High95.90
  • 52 Week High Date09/17/20
  • 52 Week Low63.90
  • 52 Week Low Date05/14/20
  • Market Cap8,060.02M
  • Shares Out82.96M
  • 10 Day Average Volume119,529.27
  • Dividend1.00
  • Dividend Yield1.26%
  • Beta0.82
  • YTD % Change16.76

RATIOS/PROFITABILITY

  • EPS (TTM)6.61
  • P/E (TTM)12.00
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date06/03/2020
  • Div Amount1.00
  • Split Date-
  • Split Factor-

Latest On Ipsen SA

There is no recent news for this security.

Latest From Our Partners

Profile

MORE
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and...
Marc de Garidel
Chairman
Antoine Flochel
Vice Chairman
David Loew
Chief Executive Officer
Aymeric le Chatelier
Chief Financial Officer
Francois Garnier
Executive Vice President
Address
65 Quai Georges Gorse
Boulogne-billancourt
92100
France